ESPR

Companies
NASDAQ
Esperion Therapeutics Inc.
Health Care
Price Chart
Overview

About ESPR

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Market Cap
$530.5M
Volume
8.5M
Avg. Volume
7.0M
P/E Ratio
4.5435
Dividend Yield
0.00%
Employees
200.0

Company Information

Exchange
NASDAQ
Sector
Health Care
Industry
Drug Manufacturers - Specialty & Generic
Risk & Correlation Analysis
Market Correlation
1.63
High Correlation
Volatility
High (0.83)
Relative to market

Macro Factor Sensitivities

Interest Rates
Low Sensitivity
Inflation
Low Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for ESPR.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, ESPR shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
Market Cap$530.5M
Volume8.5M
P/E Ratio4.54
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 6, 2025

PortfolioPilot Analysis

Get AI-powered insights on how ESPR fits into your investment strategy and portfolio diversification.

Pricing info last updated June 17, 2025 (after market close)Other info last updated April 2, 2025